# Neopenda

> Neopenda is a Chicago-headquartered public benefit corporation that makes neoGuard, a battery-powered wearable system for continuously monitoring pulse rate, respiratory rate, blood oxygen saturation and temperature in resource-constrained hospitals. A set of sensors sends data to a shared tablet dashboard so one clinician can watch multiple patients and respond to deterioration sooner. The company sells devices, accessories, training and support to hospitals, governments, NGOs and distributors, with commercial deployments concentrated in Kenya, Uganda and Ghana.

- **Founded:** 2015
- **Headquarters:** Chicago, United States
- **Founders:** Sona Shah (CEO and Co-Founder), Teresa Cauvel (CTO and Co-Founder)
- **Team size:** 2-10 employees on LinkedIn; the company site names a six-person leadership and core engineering team and describes additional regional sales and operations staff.
- **Products:** neoGuard, NeoMonitor dashboard, Implementation, training and support
- **Notable:** Received EU CE marking in 2021 and later maintained Class IIb certification., Built an ISO 13485-certified quality management system., Registered neoGuard in Kenya and Tanzania and secured patents in the United States, Japan and Kenya.

## Products & services

- **neoGuard** — A reusable, battery-powered wearable that continuously measures pulse rate, respiratory rate, blood oxygen saturation and temperature, sending readings and alerts wirelessly to the NeoMonitor tablet dashboard.
- **NeoMonitor dashboard** — A tablet application that displays real-time readings and alerts from up to 15 neoGuard devices so one clinician can prioritize patients across a ward.
- **Implementation, training and support** — Installation, clinician training and customer support sold with device deployments to help facilities incorporate continuous monitoring into routine care.

## Achievements

- Received EU CE marking in 2021 and later maintained Class IIb certification.
- Built an ISO 13485-certified quality management system.
- Registered neoGuard in Kenya and Tanzania and secured patents in the United States, Japan and Kenya.
- Published peer-reviewed feasibility, accuracy, acceptability and parent-perception research from Uganda, Kenya and Nigeria.
- Reported 500+ devices sold, 5,000+ patients monitored and 150,000+ monitoring hours by 2026.
- Included in the WHO 2024 compendium of innovative health technologies for low-resource settings and the 2024 Unitaid oxygen innovation landscape.
- Won the 2018 MIT Solve Frontlines of Health challenge and a 2019 Fourth Revolution Product of the Year award.
- Co-founders were named to Inc.'s 30 Under 30 list in 2017.

## Latest updates

- **2026-08** — Neopenda reported installations and clinician training at its first three partner hospitals in Kericho County, Kenya.
- **2026-06** — The company reported 150-device public orders: 50 devices for Kakamega County General Hospital and 100 for Kericho County.
- **2026-05** — Its community campaign page reported $1.19 million raised from 224 investors.
- **2026-04** — Grand Challenges Canada described public neoGuard orders from Kakamega, Migori and Kericho counties and said a structured procurement model cut the typical 18-24 month sales cycle by at least half.
- **2025-05** — Neopenda announced a milestone-based CAD $1 million Transition to Scale grant from Grand Challenges Canada.
- **2025-04** — A ten-year company update said more than 45 hospitals across Kenya, Uganda and Ghana had purchased neoGuard.

## Links

- Website: https://www.neopenda.com/
- LinkedIn: https://www.linkedin.com/company/neopenda
- Twitter/X: https://twitter.com/Neopenda_Health
- Instagram: https://www.instagram.com/neopendahealth/
- Facebook: https://www.facebook.com/Neopenda

---

Profile page: https://yespress.io/neopenda
Published by YesPress — https://yespress.io
Last updated: 2026-08-22